ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
115 hedge funds and large institutions have $354M invested in ChemoCentryx, Inc. in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 30 reducing their positions, and 13 closing their positions.
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
37% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 30
15% more funds holding
Funds holding: 100 → 115 (+15)
6% more capital invested
Capital invested by funds: $335M → $354M (+$18.6M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less call options, than puts
Call options by funds: $579K | Put options by funds: $691K
Top Buyers
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$7.61M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.84M |
| 3 |
Two Sigma Advisers
New York
|
+$2.72M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.65M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$2.39M |
Top Sellers
CCXI Hedge Fund Activity: Q2 2018 in Review
115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q2 2018, worth a combined $354M — up 5.5% from $335M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CCXI positions and 13 closed out — a net gain of 16 holders — while 41 added to existing stakes and 30 trimmed.
The largest buyer was Carmignac Gestion, adding an estimated $7.61M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $6.26M sold.
- 115 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q2 2018, up from 100 in Q1 2018.
- Funds reported $354M of ChemoCentryx, Inc. stock for Q2 2018, up 5.5% quarter-over-quarter.
- 29 funds opened new ChemoCentryx, Inc. positions in Q2 2018 and 13 closed out, a net change of +16 holders.
- The largest ChemoCentryx, Inc. buyer in Q2 2018 was Carmignac Gestion, an estimated $7.61M added.
- The largest ChemoCentryx, Inc. seller in Q2 2018 was T. Rowe Price Associates, an estimated $6.26M sold.
Based on aggregated 13F filings for Q2 2018.